Possibly, based on our currently presented data and previous studies, during chemo-immunotherapy applied in clinics with anti-GD2 ganglioside antibodies and chemotherapeutics, expression of ABCB1 transporter could be decreased, and neuroblastoma tumors might become more sensitive to chemotherapy. This evidence concerns the gene ABCB1 and neuroblastoma.